Clinical Trial Search

Primary: The Sensitivity of Blinded Visual Interpretations of [18F]Flutemetamol Positron Emission Tomography (PET) Images Without Anatomic Brain Images for Detecting Brain…

Primary: Difference Between Heart Rate Variability Between Intravenous and Subcutaneous Group — 1.0; 2.6 none (ratio) — p=0.05

Primary: Time-Weighted Mean Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale — -21.40; -19.76 Score on a Scale — p=0.390

Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters

Primary: Percentage of Patients Failure Free at 2 Years Following Study Entry — 36 percentage of participants

Primary: Number of Participants With Confirmed Virologic Response (CVR) at Week 48 — 40 Participants

Primary: Mean Change From Baseline in Contact Lens-Related Dryness Symptoms at Week 1 and Week 2 — -0.09; -0.29 Units on a scale

Primary: Number of Air Microemboli Registered Over the Middle Cerebral Arteries by On-line Trans-cranial Echo-Doppler (TCD). — 41; 118 Air Microemboli — p=<0.01

Primary: Change From Baseline to End of Study in Bone Formation Rate (BFR) — -488 μm^2/mm^2/day

Primary: Percentage Change in Inflammatory Lesions From Baseline to End of Treatment — -20.3; -29.4 percentage of change

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) From Visit 1 to the End of Study (Approximately 61 Weeks) — 37 participants

Primary: Clinical Global Impression - Improvement (CGI-I) at End of Administration/Observation — 23; 38; 25; 32 Participants

Primary: Consecutive Weeks of Marijuana Abstinence — 3.55; 2.82; 0.78 consecutive weeks of abstinence — p=<0.05

Primary: Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) — 22.3; 22.2; -4.7; -4.0 mm Hg

Primary: Clinical Response — 9 Participants — p=0.03